EULAR recommendations for the management of Behçet disease

Annals of the Rheumatic Diseases

Volumn 67, Issue 12, 2008, Pages 1656-1662

  Hatemi, G ^a   Silman, A ^b   Bang, D ^c   Bodaghi, B ^d   Chamberlain, A M ^e   Gul, A ^f   Houman, M H ^g   Kotter I ^h   Olivieri, I ⁱ   Salvarani, C ^j   Sfikakis, P P ^k   Siva, A ^l   Stanford, M R ^m   Stubiger N ^h   Yurdakul, S ^a   Yazici, H ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Yonsei University   (South Korea)

^d SORBONNE UNIVERSITÉ   (France)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f ISTANBUL UNIVERSITY   (Turkey)

^g LA RABTA HOSPITAL   (Tunisia)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁱ SAN CARLO HOSPITAL   (Italy)

^j Athens University ^*  (Italy)

^k UNIVERSITY OF ATHENS   (Greece)

^l ISTANBUL UNIVERSITY   (Turkey)

^m KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZAPROPAZONE; AZATHIOPRINE; BENZATHINE PENICILLIN; CHLORAMBUCIL; CHLORHEXIDINE; COLCHICINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; INDOMETACIN; INFLIXIMAB; LIDOCAINE; METHOTREXATE; METHYLPREDNISOLONE; MINOCYCLINE; OXAPROZIN; PLACEBO; SALAZOSULFAPYRIDINE; STEROID; SUCRALFATE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ZINC;

ANEURYSM; ANTICOAGULATION; ARTHRITIS; ARTICLE; ARTIFICIAL EMBOLISM; BEHCET DISEASE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BUDD CHIARI SYNDROME; CANCER RISK; CATARACT; CEREBRAL SINUS THROMBOSIS; CLINICAL TRIAL; CYTOPENIA; DEEP VEIN THROMBOSIS; DEPRESSION; DIGESTIVE SYSTEM ULCER; DRUG MEGADOSE; ERYTHEMA NODOSUM; EYE DISEASE; EYE INFLAMMATION; GENITAL ULCER; GLAUCOMA; HEALTH CARE PERSONNEL; HEMICOLECTOMY; HUMAN; HYPERTENSION; HYPOPYON; KIDNEY DYSFUNCTION; LEG ULCER; MOUTH ULCER; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; PERIPHERAL NEUROPATHY; POSTTHROMBOSIS SYNDROME; PRIORITY JOURNAL; PULMONARY ARTERY ANEURYSM; RETINA VASCULITIS; SIDE EFFECT; TERATOGENICITY; THROMBOPHLEBITIS; UNSPECIFIED SIDE EFFECT; UVEITIS; VEIN THROMBOSIS; VISUAL ANALOG SCALE;

ANTICOAGULANTS; ARTHRITIS; BEHCET SYNDROME; CYCLOSPORINE; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL DISEASES; HUMANS; INTERNATIONAL COOPERATION; NERVOUS SYSTEM DISEASES; SKIN DISEASES; UVEITIS; VASCULAR DISEASES;

EID: 56749168836     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2007.080432     Document Type: Article

References (110)

1. Yazici H, Tuzun Y, Pazarli H, Yurdakul S, Ozyazgan Y, Ozdogan H, et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behcet's syndrome. Ann Rheum Dis 1984;43:783-9.
2. Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003;82:60-76.
3. Dougados M, Betteridge N, Burmester GR, Euller-Ziegler L, Guillemin F, Hirvonen J, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004;63:1172-6.
4. The AGREE Collaboration Appraisal of Guidelines for Research and Evaluation (AGREE) Instrument. http://www.agreecollaboration.org (accessed 21 January 2007).
5. Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 1990;322:281-5.
6. Hamuryudan V, Ozyazgan Y, Hizli N, Mat C, Yurdakul S, Tuzun Y, et al. Azathioprine in Behçet's syndrome: effects on long-term prognosis. Arthritis Rheum 1997;40:769-74.
7. Ozyazgan Y, Yurdakul S, Yazici H, Tuzun B, Iscimen A, Tuzun Y, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. Br J Ophthalmol 1992;76:241-3.
8. BenEzra D, Cohen E, Chajek T, Friedman G, Pizanti S, de Courten C, et al. Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome. Transplant Proc 1988;20(3 Suppl 4):136-43.
9. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet 1989;1:1093-6.
10. Atmaca LS, Batioglu F. The efficacy of cyclosporin-a in the treatment of Behçet's disease. Ophthalmic Surg 1994;25:321-7.
11. Chavis PS, Antonios SR, Tabbara KF. Cyclosporine effects on optic nerve and retinal vasculitis in Behçet's disease. Doc Ophthalmol 1992;80:133-42.
12. Ermakova NA. Efficacy of corticosteroids and cyclosporin in the treatment of retinal vasculitis in patients with Behçet's disease. Adv Exp Med Biol 2003;528:563-5.
13. Fujino Y, Joko S, Masuda K, Yagi I, Kogure M, Sakai J, et al. Ciclosporin microemulsion preconcentrate treatment of patients with Behçet's disease. Jpn J Ophthalmol 1999;43:318-26.
14. Hayasaka S, Kawamoto K, Noda S, Kodama T. Visual prognosis in patients with Behçet's disease receiving colchicine, systemic corticosteroid or cyclosporin. Ophthalmologica 1994;208:210-3.
15. Ozdal PC, Ortac S, Taskintuna I, Firat E. Long-term therapy with low dose cyclosporin A in ocular Behçet's disease. Doc Ophthalmol 2002;105:301-12.
16. Pacor ML, Biasi D, Lunardi C, Cortina P, Caramaschi P, Girelli D, et al. Cyclosporin in Behçet's disease: results in 16 patients after 24 months of therapy. Clin Rheumatol 1994;13:224-7.
17. Sajjadi H, Soheilian M, Ahmadieh H, Hassanein K, Parvin M, Azarmina M, et al. Low dose cyclosporin-A therapy in Behçet's disease. J Ocul Pharmacol 1994;10:553-60.
18. Sullu Y, Oge I, Erkan D, Ariturk N, Mohajeri F. Cyclosporin-A therapy in severe uveitis of Behçet's disease. Acta Ophthalmol Scand 1998;76:96-9.
19. Whitcup SM, Salvo EC Jr, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's disease. Am J Ophthalmol 1994;118:39-45.
20. Nussenblatt RB, Palestine AG, Chan CC, Mochizuki M, Yancey K. Effectiveness of cyclosporin therapy for Behçet's disease. Arthritis Rheum 1985;28:671-9.
21. Muftuoglu AU, Pazarli H, Yurdakul S, Yazici H, Ulku BY, Tuzun Y, et al. Short term cyclosporin A treatment of Behçet's disease. Br J Ophthalmol 1987;71:387-90.
22. Wechsler B, Mertani EB, le Hoang P, de Groc F, Piette JC, Beaufils H, et al. Cyclosporin A is effective, but not safe, in the management of Behçet's disease. Arthritis Rheum 1986;29:574-5.
23. Diaz-Llopis M, Cervera M, Menezo JL. Cyclosporin A treatment of Behçet's disease: a long-term study. Curr Eye Res 1990;9(Suppl):17-23.
24. Binder AI, Graham EM, Sanders MD, Dinning W, James DG, Denman AM. Cyclosporin A in the treatment of severe Behçet's uveitis. Br J Rheumatol 1987;26:285-91.
25. Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, et al. Anti-TNF therapy in the management of Behçet's disease - review and basis for recommendations. Rheumatology (Oxford) 2007;46:736-41.
26. Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inane M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum 2005;52:2478-84.
27. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med 2004;140:404-6.
28. Ohno S, Nakamura S, Hon S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 2004;31:1362-8.
29. Wechsler B, Sable-Fourtassou R, Bodaghi B, Huong DL, Cassoux N, Badelon I, et al. Infliximab in refractory uveitis due to Behçet's disease. Clin Exp Rheumatol 2004;22(4 Suppl 34):S14-6.
30. Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease. Int Ophthalmol 2005;26:83-92.
31. Arayssi T, Hamra R, Homeidan F, Uthman I, Awwad ST, Mroue K, et al. The efficacy of a single dose of infliximab in the treatment of Behçet's disease uveitis. Clin Exp Rheumatol 2005;23:427.
32. Giansanti F, Barbera ML, Virgili G, Pieri B, Emmi L, Menchini U. Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behçet disease. Eur J Ophthalmol 2004;14:445-8.
33. Lanthier N, Parc C, Scavennec R, Dhote R, Brezin AP, Guillevin L. Infliximab in the treatment of posterior uveitis in Behçet's disease. Long term follow up in four patients. Presse Med 2005;34:916-8.
34. Morris DS, Gavin MP, Sturrock RD. The effect of anti-tumour necrosis factor α (infliximab) on sight-threatening uveitis in a patient with Behçet's disease. Adv Exp Med Biol 2003;528:557-9.
35. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, Schlincker A, Martin-Mola E. Effect of infliximab on threatening panuveitis in Behçet's disease. Lancet 2001;358:1644.
36. Sayarlioglu M, Cinal A, Topcu N, Demirok A. Effect of infliximab on refractory uveitis in Behçet's disease. Ann Pharmacother 2004;38:901-2.
37. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001;358:295-6.
38. Triolo G, Vadala M, Accardo-Palumbo A, Ferrante A, Ciccia F, Giardina E, et al. Antitumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease. Ann Rheum Dis 2002;61:560-1.
39. Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, et al. Interferon α-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002;138:467-71.
40. Kotter I, Vonthein R, Zierhut M, Eckstein AK, Ness T, Gunaydin I, et al. Differential efficacy of human recombinant interferon-α2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial. Semin Arthritis Rheum 2004;33:311-9.
41. Kotter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Günaydin I, et al. Human recombinant interferon α-2a for the treatment of with sight threatening posterior or panuveitis. Br J Ophthalmol 2003;87:423-31.
42. Wechsler B, Bodaghi B, Huong DL, Fardeau C, Amoura Z, Cassoux N, et al. Efficacy of interferon α-2a in severe and refractory uveitis associated with Behçet's disease. Ocul Immunol Inflamm 2000;8:293-301.
43. Bodaghi B, Gendron G, Wechsler B, Terrada C, Cassoux N, Huong du LT, et al. Efficacy of interferon α in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007;91:335-9.
44. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-α therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol 2006;244:1692-5.
45. Krause L, Turnbull JR, Torun N, Pleyer U, Zouboulis CC, Foerster MH. Interferon α- 2a in the treatment of ocular Adamantiades- Behçet's disease. Adv Exp Med Biol 2003;528:511-9.
46. Calguneri M, Ozturk MA, Ertenli I, Kiraz S, Apras S, Ozbalkan Z. Effects of interferon α treatment on the clinical course of refractory Behçet's disease: an open study. Ann Rheum Dis 2003;62:492-3.
47. Hamuryudan V, Ozyazgan Y, Fresko Y, Mat C, Yurdakul S, Yazici H. Interferon α combined with azathioprine for the uveitis of Behçet's disease: an open study. Isr Med Assoc J 2002;4(11 Suppl):928-30.
48. Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of interferon α in Behçet disease: review of the literature. Semin Arthritis Rheum 2004;33:320-35.
49. Cantini F, Salvarani C, Niccoli L, Padula A, Arena AI, Bellandi F, et al. Treatment of thrombophlebitis of Behçet's disease with low dose cyclosporin A. Clin Exp Rheumatol 1999;17:391-2.
50. Kahraman O, Celebi-Onder S, Kamali S, Inanc M, Ocal L, Aral O, et al. Long-term course of deep venous thrombosis in patients with Behçet's disease. In Proceedings of the American College of Rheumatology 67th Annual Scientific Meeting. Orlando, Florida. New Jersey, USA: Wiley, 2003; S385.
51. Hosaka A, Miyata T, Shigematsu H, Shigematsu K, Okamoto H, Ishii S, et al. Long-term outcome after surgical treatment of arterial lesions in Behçet disease. J Vasc Surg 2005;42:116-21.
52. Tuzun H, Besirli K, Sayin A, Vural FS, Hamuryudan V, Hizli N, et al. Management of aneurysms in Behçet's syndrome: an analysis of 24 patients. Surgery 1997;121:150-6.
53. Nitecki SS, Ofer A, Karram T, Schwartz H, Engel A, Hoffman A. Abdominal aortic aneurysm in Behçet's disease: new treatment options for an old and challenging problem. Isr Med Assoc J 2004;6:152-5.
54. Park JH, Chung JW, Jon JH, Song SY, Shin SJ, Chung KS, et al. Aortic and arterial aneurysms in Behçet disease: management with stent-grafts - initial experience. Radiology 2001;220:745-50.
55. Kwon Koo B, Shim WH, Yoon YS, Kwon Lee B, Choi O, Jang Y, et al. Endovascular therapy combined with immunosuppressive treatment for pseudoaneurysms in patients with Behçet's disease. J Endovasc Ther 2003;10:75-80.
56. Le Thi Huong D, Wechsler B, Papo T, Piette JC, Bletry O, Vitoux JM, et al. Arterial lesions in Behçet's disease. A study in 25 patients. J Rheumatol 1995;22:2103-13.
57. Hamuryudan V, Yurdakul S, Moral F, Numan F, Tuzun H, Tuzuner N, et al. Pulmonary arterial aneurysms in Behçet's syndrome: a report of 24 cases. Br J Rheumatol 1994;33:48-51.
58. Hamuryudan V, Er T, Seyahi E, Akman C, Tuzun H, Fresko I, et al. Pulmonary artery aneurysms in Behçet syndrome. Am J Med 2004;117:867-70.
59. Iida M, Kobayashi H, Matsumoto T, Okada M, Fuchigami T, Yao T, et al. Postoperative recurrence in patients with intestinal Behçet's disease. Dis Colon Rectum 1994;37:16-21.
60. Choi IJ, Kim JS, Cha SD, Jung HC, Park JG, Song IS, et al. Long-term clinical course and prognostic factors in intestinal Behçet's disease. Dis Colon Rectum 2000;43:692-700.
61. Lee JH, Kim TN, Choi ST, Jang BI, Shin KC, Lee SB, et al. Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor α monoclonal antibody (Infliximab). Korean J Intern Med 2007;22:24-7.
62. Kram MT, May LD, Goodman S, Molinas S. Behçet's ileocolitis: successful treatment with tumor necrosis factor-α antibody (infliximab) therapy: report of a case. Dis Colon Rectum 2003;46:118-21.
63. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology 2001;120:995-9.
64. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor α antibody. Gut 2001;49:725-8.
65. Brik R, Shamali H, Bergman R. Successful thalidomide treatment of severe infantile Behcet disease. Pediatr Dermatol 2001;18:143-5.
66. Aktulga E, Altac M, Muftuoglu A, Ozyazgan Y, Pazarli H, Tuzun Y, et al. A double blind study of colchicine in Behçet's disease. Haematologica 1980;65:399-402.
67. Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Uysal O, et al. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum 2001;44:2686-92.
68. Calguneri M, Kiraz S, Ertenli I, Benekli M, Karaarslan Y, Celik I. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet's disease. A randomized clinical trial. Arthritis Rheum 1996;39:2062-5.
69. Simsek H, Dundar S, Telatar H. Treatment of Behçet disease with indomethacin. Int J Dermatol 1991;30:54-7.
70. Takeuchi A, Mori M, Hashimoto A, Chihara T. Efficacy of oxaprozin in the treatment of articular symptoms of Behçet's disease. Clin Rheumatol 1984;3:397-9.
71. Moral F, Hamuryudan V, Yurdakul S, Yazici H. Inefficacy of azapropazone in the acute arthritis of Behçet's syndrome: a randomized, double blind, placebo controlled study. Clin Exp Rheumatol 1995;13:493-5.
72. Mat C, Yurdakul S, Uysal S, Gogus F, Ozyazgan Y, Uysal O, et al. A double-blind trial of depot corticosteroids in Behçet's syndrome. Rheumatology (Oxford) 2006;45:348-52.
73. Hamuryudan V, Moral F, Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, et al. Systemic interferon α2b treatment in Behçet's syndrome. J Rheumatol 1994;21:1098-100.
74. Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, et al. Short-term trial of eanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 2005;32:98-105.
75. Hirohata S, Suda H, Hashimoto T. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease. J Neurol Sci 1998;159:181-5.
76. Kikuchi H, Aramaki K, Hirohata S. Low dose MTX for progressive neuro-Behçet's disease. A follow-up study for 4 years. Adv Exp Med Biol 2003;528:575-8.
77. O'Duffy JD, Robertson DM, Goldstein NP. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease. Am J Med 1984;76:75-84.
78. Nichols JC, Ince A, Akduman L, Mann ES. Interferon-α2a treatment of neuro-Behçet disease. J Neuroophthalmol 2001;21:109-11.
79. Fujikawa K, Aratake K, Kawakami A, Aramaki T, Iwanaga N, Izumi Y, et al. Successful treatment of refractory neuro-Behçet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile. Ann Rheum Dis 2007;66:136-7.
80. Alty JE, Monaghan TM, Bamford JM. A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNFα blockade. Clin Neurol Neurosurg 2007;109:279-81.
81. Ribi C, Sztajzel R, Delavelle J, Chizzolini C. Efficacy of TNFα blockade in cyclophosphamide resistant neuro-Behçet disease. J Neurol Neurosurg Psychiatry 2005;76:1733-5.
82. Sarwar H, McGrath H Jr, Espinoza LR. Successful treatment of long-standing neuro-Behçet's disease with infliximab. J Rheumatol 2005;32:181-3.
83. Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology 1999;106:586-9.
84. Kotter I, Gunaydin I, Batra M, Vonthein R, Stubiger N, Fierlbeck G, et al. CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications - results of a retrospective analysis of 117 cases. Clin Rheumatol 2006;25:482-6.
85. Kato Y, Numaga J, Kato S, Kaburaki T, Kawashima H, Fujino Y. Central nervous system symptoms in a population of Behçet's disease patients with refractory uveitis treated with cyclosporine A. Clin Experiment Ophthalmol 2001;29:335-6.
86. Serdaroglu P, Yazici H, Ozdemir C, Yurdakul S, Bahar S, Aktin E. Neurologic involvement in Behçet's syndrome. A prospective study. Arch Neurol 1989;46:265-9.
87. Alpsoy E, Er H, Durusoy C, Yilmaz E. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study. Arch Dermatol 1999;135:529-32.
88. Mumcu G, Ergun T, Elbir Y, Eksioglu-Demiralp E, Yavuz S, Atalay T, et al. Clinical and immunological effects of azithromycin in Behçet's disease. J Oral Pathol Med 2005;34:13-6.
89. Kaneko F, Oyama N, Nishibu A. Streptococcal infection in the pathogenesis of Behçet's disease and clinical effects of minocycline on the disease symptoms. Yonsei Med J 1997;38:444-54.
90. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:443-50.
91. Gardner-Medwin JM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiotogical studies to detect thalidomide neuropathy. Ann Rheum Dis 1994;53:828-32.
92. Saylan T, Saltik I. Thalidomide in the treatment of Behçet's syndrome. Arch Dermatol 1982;118:536.
93. Hamza MH. Treatment of Behçet's disease with thalidomide. Clin Rheumatol 1986;5:365-71.
94. Alpsoy E, Yilmaz E, Basaran E. Interferon therapy for Behçet's disease. J Am Acad Dermatol 1994;31:617-9.
95. Azizlerli G, Sarica R, Kose A, Ovul C, Kavala M, Kayabali M, et al. Interferon α-2a in the treatment of Behçet's disease. Dermatology 1996;192:239-41.
96. Boyvat A, Sisman-Solak C, Gurler A. Long-term effects of interferon α2A treatment in Behçet's disease. Dermatology 2000;201:40-3.
97. Georgian S, Monastirli A, Pasmatzi E, Gartaganis S, Goerz G, Tsambaos D. Efficacy and safety of systemic recombinant interferon-α in Behçet's disease. J Intern Med 1998;243:367-72.
98. O'Duffy JD, Calamia K, Cohen S, Goronzy JJ, Herman O, Jorizzo J, et al. Interferon-α treatment of Behçet's disease. J Rheumatol 1998;25:1938-44.
99. Zouboulis CC, Treudler R, Orfanos CE. Adamantiades-Behçet disease. Therapeutic administration of systemic recombinant interferon-α- 2a. Hautarzt 1993;44:440-5.
100. Bertsias GK, Ioannidis JP, Boletis J, Bombardier S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erytematosus (SLE). Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. Published Online First: 15 May 2007. doi:10.1136/ard.2007. 070367
101. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605-17.
102. Zhang W, Doherty M, Leeb BF, Alekseeva L, Arden NK, Bijlsma JW, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:377-88.
103. Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, et al. EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11.
104. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
105. Combe B, Landewe R, Lukas C, Bolosiu HO, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45.
106. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics IESCISIT). Ann Rheum Dis 2005;64:669-81.
107. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55.
108. Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JW, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000;59:936-44.e.
109. Yazici H. Use and abuse of the controlled clinical trial. Bull NYU Hosp Jt Dis 2007;65:132-4.
110. Sut N, Seyahi E, Yurdakul S, Senocak M, Yazici H. A cost analysis of Behçet's syndrome in Turkey. Rheumatology (Oxford) 2007;46:678-82.